Evidence map›Paper›PMID 41467947›Full record

ArticleDiscover oncology2025

Integrating multi-omics data and machine learning to identify endocrine disrupting chemicals targeting key ccRCC-related genes.

Mengzhuo Zheng, Debiao Wang, Bo Guan, Liyu Cao

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mengzhuo Zheng *College of Informatics, Huazhong Agricultural University, Wuhan, 430070, China.
Debiao Wang *Department of Pathology, School of Basic Medical Science, Anhui Medical University, Hefei, 230032, China.
Bo GuanDepartment of Urology, Fuyang People's Hospital, Fuyang, 236000, China.
Liyu CaoDepartment of Pathology, School of Basic Medical Science, Anhui Medical University, Hefei, 230032, China. caoliyuhf@163.com.

Funding

Clinical Medical Research Translation Special Foundation of Anhui Province 202204295107020031Clinical Medical Research Translation Special Foundation of Anhui Province 202204295107020052Scientific research project of Fuyang Health Commission of Anhui Province FY2021-003
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is a highly aggressive and metastatic malignancy that poses a serious threat to patient health. While its development involves both genetic and environmental influences, the interactions between genetic susceptibility and endocrine-disrupting chemicals (EDCs) remain poorly understood. In this study, we integrated multi-omics datasets and applied machine learning approaches to identify EDCs and their associated target genes implicated in ccRCC pathogenesis. We analyzed bulk and single-cell RNA sequencing data and evaluated 101 machine learning algorithms to construct a robust prognostic model. This analysis identified 8 EDCs potentially involved in ccRCC: Diethylnitrosamine, Diethylstilbestrol, Resveratrol, 4,4'-diaminodiphenylmethane, Trichloroethylene, Arsenic, Lead, and 2,3,5-(triglutathion-S-yl)hydroquinone. 5 EDC-associated prognostic genes-BIRC5, CCND1, RRM2, CDH1, and TRIB3-were also identified. Pathway enrichment and immune infiltration analyses revealed intricate interactions between these genes and the tumor microenvironment. Furthermore, cell-cell communication analysis revealed distinct signaling patterns among EDC-associated subpopulations, offering new insights into how EDCs may modulate gene expression and contribute to ccRCC progression. This study provides a foundation for future investigations into EDC-driven tumor biology and may guide the development of targeted therapies and preventative strategies against ccRCC.

Indexed as

ccRCCCell-cell communicationEDCImmune infiltrationMachine learningRNA-seq

Identifiers

PMID41467947
PMCPMC12864628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.